Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Target Price
The average target price of NXTC is 17 and suggests 93% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell